Navigate Up
Launch the Developer Dashboard
Resources and information on the COVID-19 pandemic with a focus on the intersection with the HIV pandemic

COVID-19 and terminology

Coronavirus disease 2019 (COVID-19) is the infectious disease caused by the most recently discovered coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019. The new virus that causes COVID-19 illness has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
According to the World Health Organization: the most common symptoms of COVID-19 are fever, tiredness, and dry cough. Some patients may have aches and pains, nasal congestion, runny nose, sore throat or diarrhea. These symptoms are usually mild and begin gradually. Some people become infected but don’t develop any symptoms and don't feel unwell. Most people (about 80%) recover from the disease without needing special treatment. Around 1 out of every 6 people who gets COVID-19 becomes seriously ill and develops difficulty breathing. Older people, and those with underlying medical problems like high blood pressure, heart problems or diabetes, are more likely to develop serious illness. People with fever, cough and difficulty breathing should seek medical attention.
Background on coronaviruses from the NIH: “Coronaviruses are a large family of viruses that usually cause mild to moderate upper-respiratory tract illnesses, like the common cold, in people. However, three times in the 21st century coronavirus outbreaks have emerged from animal reservoirs to cause severe disease and global transmission concerns.
There are hundreds of coronaviruses, most of which circulate among animals including pigs, camels, bats and cats. Sometimes those viruses jump to humans—called a spillover event—and can cause disease. Seven coronaviruses are known to cause human disease, four of which are mild: viruses 229E, OC43, NL63 and HKU1. Three of the coronaviruses can have more serious outcomes in people, and those diseases are SARS (severe acute respiratory syndrome) which emerged in late 2002 and disappeared by 2004; MERS (Middle East respiratory syndrome), which emerged in 2012 and remains in circulation in camels; and COVID-19, which emerged in December 2019 from China and a global effort is under way to contain its spread. COVID-19 is caused by the coronavirus known as SARS-CoV-2.
Thanks to research investments into the SARS and MERS outbreaks, NIAID scientists and grantees are better prepared to develop diagnostics, therapeutics and vaccines against COVID-19. Included in those projects are basic research to understand how the virus infects cells and causes disease; adapting platforms used to develop diagnostic tests and vaccines; and evaluating treatments such as broad-spectrum antivirals and potentially monoclonal antibodies.”

Note: COVID-19 is an emerging, rapidly evolving situation.

The CDC has a FAQ page dedicated to COVID-19: What people with HIV should know.

  • ​The CDC notes that although the risk of serious illness from COVID-19 for people with HIV is not known, people with HIV may have concerns and questions related to their risk. This is an emerging, rapidly evolving situation and the CDC will provide updated information as it becomes available.



The Interim Guidance for COVID-19 and Persons with HIV is now available on the AIDSinfo website. The guidance, which was developed collectively by the U.S. Department of Health and Human Services Antiretroviral and Opportunistic Infections Guidelines Panels, which are working groups of the Office of AIDS Research Advisory Council, is intended for health care providers and persons living with HIV in the United States.

NIH HIV/AIDS Clinical Trials Networks
The NIH HIV/AIDS Clinical Trials Networks (ACTG, HPTN, HVTN, IMPAACT and MTN) have all recently issued guidance on the status of new and ongoing studies. They are all listed here. In general, for most studies, ​opening of new studies will be on hold and screening and enrollment in ongoing studies will be paused. Visits in ongoing studies will be continued, subject to local challenges or constraints. For the status of ongoing studies, refer to the guidance. Contact your site or network if you have questions about specific ongoing studies. Additional guidance specific to laboratories is posted here​.
From the European Medicines Agency (EMA) and collaboratorsGuidance on the Management of Clinical Trials during the COVID 19 (Coronavirus) pandemic. (Version 1- 20/03/2020).
FDA Guidance on Conduct of Clinical Trials of Medical Products during the COVID-19 Pandemic at:
Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19 (Notice Number: NOT-OD-20-87)at:
Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19 (Notice Number: NOT-OD-20-86)at:
NCI Interim Guidance for Patients on Clinical Trials Supported by the NCI Cancer Therapy Evaluation Program and the NCI Community Oncology Research Program (NCORP).


SAHPRA Policy on Conduct of Clinical Trials of Health Products During the Current Covid-19 Pandemic. The South African Health Products Regulatory Authority (SAHPRA) is committed to providing timely health products regulatory guidance in support of continuity for stakeholders and appropriate timely regulatory response during the current COVID-19 pandemic. Specifically, this communication provides assistance to sponsors and applicants including clinical research organizations (CROs) in assuring the safety of trial participants, maintaining compliance with current good clinical practice (GCP), and minimising risks to trial integrity during the COVID-19 pandemic. Issued 25 March 2020.

World Health Organization key reference links on HIV-COVID-19:


American Academy of HIV Medicine

Considerations & Suggested Practices for Ambulatory HIV Specialty Care During Covid-19 Pandemic.


  • As part of the American Academy of HIV Medicine’s commitment to provide relevant and useful information during the COLVID-19 pandemic, please find attached a Spanish translation of the newly released guidance on COVID-19 and HIV care. Many thanks to Centro Ararat and their Chief Medical Officer and Academy member Dr. Iván Meléndez-Rivera for developing and distributing this useful resource.  Click here to view the downloadable PDF.

Infectious Disease Society of America (IDSA)/HIVMA 

From the Infectious Disease Society of America (IDSA) and the HIV Medical Association (HIVMA): COVID-19: Special Considerations for People with HIV (Version: April 17, 2020)


From the Infectious Disease Society of the USA (IDSA): a compilation of COVID-related policies and protocols, as well as coverage and payment-related information and will be updated as resources and new information becomes available.


IDSA and HIVMA Lead Call for Data-driven Public Health and Medical Responses to COVID-19:
As infectious diseases and HIV specialists on the frontlines of responses to COVID-19 across the country, members of the Infectious Diseases Society of America and its HIV Medicine Association welcome the president's announcement Sunday (March 29, 2020) that he has amended his projected duration for stay-at-home and physical distancing guidelines to last at least through April based on medical and public health guidance. With a letter signed by 60 organizations representing health professionals, patients, and advocates, and with a petition signed by more than 2,000 individuals to date, IDSA and HIVMA are leading a call for President Trump to ensure that all of his administration’s responses to the ongoing public health crises posed by the spread of COVID-19 are based on the most current medical and public health guidance available. As health professionals confronting the grim and tragic consequences of uncontained and escalating outbreaks of a new virus for which no vaccination or proven treatment yet exist, we are urging the President and Vice President Pence to continue to respond, and, where needed and advised, strengthen responses to scientific expertise and to data showing:
  • Continuing needs for rigorous public health measures that include consistent and effective social distancing guidelines, and measures that support and enforce their uniform compliance;
  • For the equipment necessary to protect health workers, treat patients and save lives;
  • And to reinforce responses with meaningful economic, nutritional and educational support for all Americans whose lives and livelihoods are disrupted by efforts to control this pandemic.
The organizational letter and the public petition were presented to the President on March 30, 2020. The IDSA continues to gather signatures on the petition. This is the IDSA link to considering adding your name.


From the British HIV Association: (8 April 2020)
We understand that some people living with HIV have received text messages advising them to shield and completely self-isolate for three months. We are currently investigating who received these messages and why this has happened. In the meantime, the British HIV Association (BHIVA) has contacted all members and added a message to the BHIVA website to reassure people living with well controlled HIV that they are not at any greater risk of COVID-19. There is no evidence, nor guidance, that people with well controlled HIV should shield. BHIVA and the Terrence Higgins Trust recommend that only people whose immune system is known to be very weak as shown by a CD4 count of less than 50, or who have had a serious illness due to suppression of the immune system in the last 6 months, should be encouraged to follow the shielding advice. These are anxious times for everyone, but we are urging people living with HIV not to panic. We will continue to monitor the latest developments and provide updated guidance if and when necessary.

BHIVA guidance for the management of adults with HIV on antiretroviral treatment (ART) during the coronavirus pandemic. (Published May 1, 2020). All BHIVA statements related to COVID-19 are available on the website: 

HIV Treatment Bulletin (HTB)

 The 27 March 2020 edition of HIV TREATMENT BULLETIN (HTB) is on the global health crisis related to the new coronavirus (SARS CoV-2) and COVID-2019 and the effect it will have for people living with HIV. HTB notes that “given the rapid pace of information, advice, research and recommendations about COVID-19, many of the links and information might either soon be outdated – or superseded. As with all health information, please check the date. The importance of updating information online, even after it has been published, means that this issue includes many links, rather than using current online text. i-Base also has a COVID-19 page for new links and updates over the coming weeks and months. selected links are just a small selection and they will likely only have a limited shelf-life. We have only included research that is available as open access papers. And it is notable that the urgency of the crisis has called for all papers to become open access. Thanks especially to Lynda Dee, Richard Jefferys, Jules Levin, Michael Louella, Jeff Taylor and Nelson Vergel. Community forums include: AIDS Treatment Activist Coalition (ATAC), European AIDS Treatment Group (EATG), ATAC Immune-Based Treatment (ATAC-IBT), International Treatment Preparedness Coalition (ITPC) and the UK Community Advisory Board (UK-CAB).”

From NAM’s aidsmap.comNo increased coronavirus risk for people with well-controlled HIV say WHO, but how will health systems cope? “The first data from Wuhan, China suggest that people living with HIV suffered no worse a coronavirus epidemic than other people in the city, confirming the World Health Organization’s position that people with well-controlled HIV do not appear to be at elevated risk of coronavirus infection or severe disease. Nonetheless, the risk of disruption to HIV services is significant, especially as the new coronavirus spreads to countries with fragile health systems. “We are bracing ourselves for an even larger pandemic in lower and middle-income countries,” Dr Meg Doherty, the new director of HIV programmes at the World Health Organization (WHO) told a webinar organised by the International AIDS Society yesterday.”
References listed in the NAM article:

Positive Women’s Ne​twork-USA

#WeGotThis: To Our PWN Family Regarding the Coronavirus Epidemic (March 13, 2020)


POZ Magazine

​From POZ Magazine: What People With HIV Need to Know About the New Coronavirus

What People With HIV Need to Know About the New Coronavirus?


HIV and SARS-CoV-2: What Are the Risks?
Josep M. Llibre, MD, PhD (April 1, 2020)- posted in full on the Clinical Care options website.
HIV and COVID-19 Risk
There are basically 3 categories of patients with HIV to consider in terms of COVID-19 risk: 1) of COVID-19 risk: 1) those with unsuppressed HIV viremia, 2) those with suppressed HIV viremia but immune discordance (generally defined as having a CD4+ cell count < 350 cells/mm3 despite suppressed HIV-1 RNA), and 3) those with suppressed HIV viremia and acceptable immune reconstitution (CD4+ cell count > 350 cells/mm3).
In Spain, we have sadly surpassed 100,000 cases of COVID-19 at the time of this writing (April 1, 2020), with a mortality rate of 8.9% among those diagnosed. Quite unexpectedly, we have seen that PLWH are not at increased risk of acquiring COVID-19 or of progressing to acute respiratory distress syndrome (ARDS) once infected, across the 3 risk classes defined above. For reasons that are as yet unknown, it appears that their risk may even be lower than that of the general population.
It is also not yet known whether HIV PIs could effectively inhibit the 3- chymotrypsin-like and papain-like proteases of SARS-CoV-2. Nevertheless, many PLWH are receiving ART regimens based on INSTIs rather than PIs. Therefore, potential protection from the use of HIV PIs does not seem to be a plausible explanation for the apparent decreased risk.
Viral Pathogenesis of Coronaviruses vs HIV
The absence of an increased risk for COVID-19 among PLWH is surprising because dysregulation of the immune response, particularly by T lymphocytes, seems to be highly involved in the pathologic process of COVID-19, and lymphocytopenia is a well identified risk factor for ARDS and death among individuals with COVID-19. Viral host receptors are important determinants of viral pathogenicity, tissue tropism, and host range. The key functional host receptors used by human pathogenic coronavirus surface structural spike glycoprotein (S) include angiotensin- converting enzyme 2, and the viral machinery used during cleavage and binding at the cell surface seems to be independent of the CD4 receptor and, therefore, distinct from HIV. Another difference between coronaviruses and HIV relates to viral assembly and budding. With HIV, assembly and budding take place at or near the plasma membrane, whereas coronaviruses carry out these processes at the endoplasmic reticulum.
 Therefore, currently available data on host cell entry mechanisms and the intracellular pathways harnessed by each virus suggest that HIV and coronavirus do not show cooperative pathogenesis. This information coupled with early observations suggesting that HIV infection is not associated with increased risk for SARS-CoV-2 infection or for more severe COVID-19 manifestations is very reassuring for our PLWH. This is particularly true because previous studies showing that human APOBEC3G, a member of the APOBEC3 cytidine deaminase family, was able to associate with both HIV and SARS-CoV structural proteins through a potentially similar, RNA-mediated mechanism raised concerns for potential shared pathogenesis.
COVID-19 in People With HIV: Commonly Asked Questions (posted on Medscape)
Paul E. Sax, MD (April 03, 2020)
Hello. This is Dr Paul Sax from Brigham and Women's Hospital and Harvard Medical School. If you're like me and you follow a panel of people with HIV, you've no doubt received many questions from them about COVID-19. Luckily, the Department of Health and Human Services has just issued an interim guidance that gives us some responses to those queries.
Although many of the statements in this guidance could apply to anyone, whether HIV-positive or HIV-negative, there are certain HIV-specific items that deserve emphasis. I'll summarize some of the most common questions I've been receiving and highlight where the guidance is particularly useful.
'Is COVID-19 a more severe disease in people with HIV?'
This is obviously a concern for people who have HIV, since HIV is known to be an immunosuppressive illness. However, as the guidance notes, the limited data currently available do not indicate that the disease course of COVID-19 in person with HIV differs from that in persons without HIV. And that's particularly the case for people who are stable on antiretroviral therapy (ART).
Remember, though, that about half the people with HIV in the United States are over the age of 50 and being older than 60 is considered a risk factor for severe disease, as are medical comorbidities such as diabetes and hypertension, which are increasingly common in our older HIV patients.
What about people who have more severe immunodeficiency, with a CD4 cell count < 200? Here, we'd have to assume that COVID-19 would be a more severe disease, even though we're learning that some of the disease manifestations of COVID-19 are actually immune-mediated. Nonetheless, this population is at greater risk for severe infections across the board, so they should be particularly careful to avoid exposure. The key thing for this population is to get on ART and improve their immune function.
'Do I need an extra supply of my medications?'
In these uncertain times, I would say it makes sense for people to have an extra supply of their antiretroviral medications. Many payers are now approving a 90-day prescription. And that makes a lot of sense for our patients on stable ART because they can avoid having to leave their house to go to pharmacies—and they can actually do what we're recommending, which is social distancing. I did check with the manufacturers of several of the more commonly used antiretroviral agents, and none of them have expressed any concern about shortages.
'Do I need to come in for my regular blood tests and checkups?'
Well, here, COVID-19 might be exposing an area where perhaps we may have been a little wasteful, in that probably for many of our stable HIV patients, a twice-yearly visit with blood testing is not really necessary. It has been sort of a socially nice thing to do, and you can certainly check in on other factors, but do they actually need to have their HIV viral load checked twice a year to document that they still have viral suppression? For many of them, I don't think it's necessary. And here is one of those situations where the guidance is helpful. They specifically say that for persons who have had suppressed HIV viral load and are in stable health, routine medical and laboratory visits should be postponed to the extent possible.
'Do my antiretroviral medications protect me from getting COVID-19?'
This question is not specifically covered in the guidance, but I've received it from several of my patients. They point out that SARS-CoV-2 is a virus and HIV is a virus, and they think maybe their antivirals could protect against SARS-CoV-2 also. In fact, one of the people who asked me this question is a doctor himself, although he's not an infectious disease doctor.
We have to point out that there is no evidence right now that these antiretrovirals protect against COVID-19. We also might want to point out that the initial enthusiasm about lopinavir/ritonavir being a possible treatment for this condition does not seem to be founded, at least on the basis of one randomized study that has been published.
So that's a quick summary of the interim guidance for people with HIV in the COVID-19 era, as well as some of the more common questions I've been receiving. Thank you very much for listening.


Tuberculosis and COVID-19

The Union published a statement regarding COVID-19 on 13 March 2020. They also have developed answers to a series of Frequently Asked Questions about the intersection between tuberculosis (TB) and COVID-19. These include information about the similarities between the two diseases, and guidance for how COVID-19 affects people on TB treatment or people who have recently recovered from TB. (Version 1, 25 March 2020). 
(Note: The mission of the Union is to promote national autonomy within the framework of the priorities of each country by developing, implementing and assessing anti-tuberculosis, lung health and non-communicable disease programmes as well as other public health issues.)


Behavioral and  Mental Health Care Resources


Behavioral Insights for People With COVID-19 As Well As Those Living With HIV.


From the NIH: Since the COVID-19 pandemic began, researchers with existing longitudinal cohorts and survey samples have been developing and fielding new survey items assessing various COVID-19 specific domains such as symptoms, knowledge and attitudes, adherence to various mitigation behaviors, social impacts, and economic impacts. Efforts to standardize or harmonize COVID-19 survey items, however, did not appear feasible given the urgency to field items as early as possible during the pandemic.


To minimize the proliferation of one-off survey items, encourage comparisons across samples, and facilitate data integration and collaboration, a trans-NIH working group co-led by the National Institute on Aging (NIA) and the Office of Behavioral and Social Sciences Research (OBSSR) worked to make existing COVID-19 survey items and investigator contact information available in a survey item repository. Two NIH-supported survey item platforms have made this expanding list of survey items available as a resource for researchers interested in assessing COVID-19 specific domains.


            NIH Public Health Emergency and Disaster Research Response (DR2): The National Institute of Environmental Health Sciences (NIEHS) and the National Library of Medicine (NLM) host the DR2 site which now includes a list of COVID-19 surveys and the domains assessed in the surveys. In addition to this COVID-19 list, DR2 provides a wide array of data collection tools and resources used in other public health emergencies and disasters, providing researchers with a rich repository of survey and other measurement tools that are applicable to the COVID-19 pandemic.  


            PhenX Toolkit: The PhenX Toolkit now includes a list of COVID-19 related measurement protocols drawn from the surveys listed in DR2. These COVID-19 survey protocols have not been vetted as per the PhenX consensus process but are made available for other researchers to consider, and to test as needed, before incorporating in their research studies. The PhenX Toolkit, funded by the National Human Genome Research Institute (NHGRI) and other NIH Institutes and Centers, has a large collection of well-established and vetted measurement protocols suitable to incorporate into studies involving COVID-19. 


Researchers addressing COVID-19 questions, whether population-based or for clinical research, are encouraged to consider these COVID-19 specific survey item repositories and select existing survey items or protocol modules currently being fielded. Researchers with additional survey items about to be fielded are encouraged to make them public for other researchers to consider by submitting the survey to 


This COVID-19 Quantitative Questionnaire was developed for MTN042/MTN-043, two trials in sub-Saharan Africa with pregnant (MTN-042/ Deliver) and breastfeeding (MTN-043/ B-protected) women.


COVID19 Interview Items for Vulnerable Populations. Compiled by the Center for Drug Use and HIV|HCV Research. (April 11, 2020). This site includes the following items:

·      Gwadz Qualitative Interview Guide

·      Harkness, A. (2020). The Pandemic Stress Index. University of Miami

·      Kalichman Covid-19 Assessment

·      Bennett and Elliot Qualitative Interview Guide

·      Stanford

·      COVID-19 Pandemic Social Distancing Event Items

·      N2 COVID-19 Check-in Survey Items (phone interview)

·      Benoit OTP Staff Survey

·      Benoit OTP Patients Focus Group Guide

·      Benoit People Who Use Drugs and Not Currently in Treatment Focus Group Guide

·      ATN

·      University of Miami School of Nursing and Health Studies Center of Excellence for Health Disparities Research: Measures Library - COVID-19

·      PhenX Toolkit COVID-19 Protocols

·      National Library of Medicine Disaster Research Resource

·      Gwadz Qualitative Interview Guide


The Pandemic Stress Index is a measure of behavior changes and stress related to the COVID-19 pandemic developed at the University of Miami. Harkness, A., Behar-Zusman, V., & Safren, S.A. (in press). Understanding the impact of COVID-19 on Latino sexual minority men in a US HIV hot spot. AIDS and Behavior. doi: 10.1007/s10461-020-02862-w.

A group of researchers from Nemours, CHOP and Cincinnati have developed a questionnaire designed for insertion into ongoing and new child health studies where aspects of the COVID-19 pandemic may impact study findings. The COVID-19 Exposure and Family Impact Survey (CEFIS-19), in English and Spanish.  There are also have REDCap versions. While designed for research, there may also be clinical applications. There is no charge for use, but we do ask that you register with us as this work is covered by our SAMHSA-funded Center for Pediatric Traumatic Stress in the National Child Traumatic Stress Network. Our website has COVID related materials that we have updated and, in some cases, newly developed. We hope that CEFIS and all our materials will be helpful. Please feel free to circulate these materials.  

Shared by Anne E. Kazak, Ph.D., ABPP, Director, Center for Healthcare Delivery Science, Nemours Children’s Health System, Co-Director, Center for Pediatric Traumatic Stress (, Professor, Department of Pediatrics, Thomas Jefferson University

Editor-in-Chief, American Psychologist.


SURVEY TOOL AND GUIDANCE: Rapid, simple, flexible behavioural insights on COVID-19. This document provides guidance to Member States in the WHO European Region that wish to conduct behavioural insights studies related to COVID-19.  The COVID-19 pandemic outbreak is placing an overwhelming burden on health systems and authorities to respond with effective and appropriate interventions, policies and messages. A poorly timed and managed pandemic response or transition phase can threaten the gains collectively achieved. The pandemic and its restrictions may have affected mental and physical well-being, social cohesion, economic stability as well as individual and community resilience and trust. In this complex context, understanding how, why and the context in which humans and communities respond allows to

1)  anticipate unwanted scenarios and initiate mitigating measures; and

2)  implement pandemic response measures that are better informed, situated, accepted and thus more effective.

Population surveys can explore perceptions, acceptance of restrictions, mental and physical health, behaviours, information needs, misperceptions and more.


Adolescent Trials Network (ATN) COVID Questionnaire Draft​  (Revised 4.8.20)

What is the goal of these questions?

-           Important to know how the standard of care is being affected by the pandemic.

-           Is COVID-19 affecting the specific behaviors we are looking at for our study outcomes?

-           How much of the effect is biasing away from the null?

-           This would give information into the dips or rise that we may see into different behaviors.


The Burden of COVID‐19 in People Living with HIV: A Syndemic Perspective. The emergence of the novel coronavirus disease known as COVID-19 creates another health burden for people living with HIV (PLWH) who face multiple morbidities and may be at heightened risk for severe physical health illness from COVID- 19. Our abilities to address these morbidities in PLWH must be considered alongside the socially-produced burdens that both place this population at risk for COVID-19 and heighten the likelihood of adverse outcomes. These burdens can affect the physical, emotional, and social well-being of PLWH and interfere with the delivery of effective healthcare and access to HIV treatment. We posit that a syndemic framework can be used to conceptualize the potential impact of COVID-19 among PLWH to inform the development of health programming services. AIDS Behav. 2020 Apr 18. doi: 10.1007/s10461-020-02871-9. [Epub ahead of print].


 COVID-19 Excel spreadsheet (with resources on two tabs)

 Courtesy of:

Richelle Allen, Ph.D., Assistant Professor

Director, The Safran Center for Psychological Services

Assistant Director of Clinical Training, The New School for Social Research


The Massachusetts General Hospital Psychiatry Department has an excellent set of comprehensive collated set of materials for COVID mental health generally. It isn’t like specific to living with HIV, though, but more just general public. 
The University of Miami CENTER for HIV and RESEARCH in MENTAL HEALTH (CHARM) also has an excellent list of COVID-19 Mental Health Resources.
Abstract: The COVID-19 pandemic is reinforcing health inequities among vulnerable populations, including men who have sex with men (MSM). We conducted a rapid online survey (April 2 to April 13, 2020) of COVID-19 related impacts on the sexual health of 1051 US MSM. Many participants had adverse impacts to general wellbeing, social interactions, money, food, drug use and alcohol consumption. Half had fewer sex partners and most had no change in condom access or use. Some reported challenges in accessing HIV testing, prevention and treatment services. Compared to older MSM, those 15–24 years were more likely to report economic and service impacts. While additional studies of COVID-19 epidemiology among MSM are needed, there is already evidence of emerging interruptions to HIV-related services. Scalable remote solutions such as telehealth and mailed testing and prevention supplies may be urgently needed to avert increased HIV incidence among MSM during the COVID-19 pandemic era. Sanchez, T.H., Zlotorzynska, M., Rai, M. et al. April, 29,2020. AIDS Behav (2020).


World Health Organization

The WHO Comprehensive Mental Health Action Plan 2013-2020  is the global plan that sets out the indicators that all WHO Member states have agreed to deliver in order to improve mental health for all.  This plan will be updated over the course of this year and Ministers of Health will approve the new plan for 2021-2030 in May 2021 at the World Health Assembly. 

In the coming weeks and months, the WHO will be leading discussions with governments at regional and country level on the new plan and with stakeholders more broadly. The WHO is also holding two periods of online consultation on the updates to the plan. The first opened March 9 and runs until March 22nd 2020. See here for more information. A second online consultation will be held later this year.

Mental health and COVID-19: WHO is publishing resources on mental health and COVID-19, please visit this link:


WHO also has a guide to addressing stigma associated with COVID-19:


NIH Director's Blog

From Dr. Francis Collins’ NIH Director’s Blog: Dealing with Stress, Anxiety, and Grief during COVID-19. This is a discussion with Dr. Joshua Gordon, Director of NIH’s National Institute of Mental Health, about how physical distancing can affect our mental well-being during the COVID-19 pandemic. (Posted April 7, 2020).
Webinars of interest (Mental Health and Stress Management):
Caring for Yourself & Others during the Covid-19 Pandemic: Managing Healthcare Workers’ Stress. Patricia Watson, PhD, National Center for PTSD. (March 24, 2020).
Coping with the stress of coronavirus. Luana Marques, PhD, Harvard Medical School. (April 1, 2020).
Managing Anxiety Related to Taking Care of Patients during the COVID-19 Pandemic. Presented by Cheryl Gore-Felton, PhD,  Debra Kaysen, PhD and Mickey Trockel, MD, PhD., Stanford Medicine. (April 3, 2020).
Finding the middle ground: Managing stress and anxiety while providing clinical care during the COVID-19 crisis. Presented by Steven A. Safren, PhD, ABPP, Professor of Psychology and Deborah Jones Weiss, PhD, Professor of Psychiatry and Lunthita Dutherly, EdD, University of Miami. (April 15, 2020).

Network and other COVID-19 Related Studies                                                                                                   


(ACTG A5395- opened to accrual on May 1, 2020).
Brief Description:
In December of 2019, a new illness appeared in China causing severe acute respiratory syndrome and pneumonia. The responsible virus is related to the severe acute respiratory syndrome coronavirus (SARS CoV-1), which led to an outbreak in 2003. The new virus has been named SARS-CoV-2 and the human disease is called COVID-19. There is currently no vaccine to prevent SARS-CoV-2 infection or medicine proven to treat COVID-19. Therefore, there is an urgent public health need for rapid development of new therapies.
Purpose of this Study: 
A5395 will see if hydroxychloroquine (HCQ) and azithromycin (Azithro) treatment will prevent hospitalizations and death in adults with COVID-19.
Key Requirements to Enter the Study
  • 18 years of age or older
  • Positive test of the nose or throat for COVID-19 from any respiratory specimen collected within 96 hours prior to when the first dose of study treatment is expected to be taken
  • Experiencing at least one of the following symptoms: fever, cough, or shortness of breath
  • Agreement to not participate in another COVID-19 study during the study period or take HCQ or Azithro from a source outside of the study. If a participant is hospitalized during the study, they can participate in another COVID-19 study.
Participants will have a 50/50 chance of receiving either Hydroxychloroquine (HCQ) and Azithromycin (Azithro) or Placebos. Neither the study staff nor the participants will know which arm they are in. Participants will take HCQ/Placebo two (200 mg each) capsules by mouth twice a day on the first day, followed by one 200 mg capsule twice a day for 6 days. Hydroxychloroquine/Placebo should be taken with food or milk. Participants will also take Azithro/Placebo two (250 mg each) capsules by mouth once on the first day and then one capsule (250 mg) every day for 4 additional days.
The following studies for hospitalized people are sponsored by Novartis and are being conducted by many ACTG sites around the country.
HAT-COVID is a placebo-controlled, phase 3 randomized trial of hydroxychloroquine (HCQ) alone vs HCQ + azithromycin (HCQ/Azi) vs placebo in hospitalized people with COVID-19. The primary outcome is discharge and vital status at Day 15 and will enroll people from acute care floors.
RUX-COVID is a placebo-controlled, phase 3 randomized controlled trial of ruxolitinib (RUX, a JAK 1/JAK 2 inhibitor) to prevent cytokine storm and respiratory failure.  The primary objective is death or need for ventilatory support by Day 29.  ICU status people on supplemental oxygen, but not intubated, are allowed to enter this study. 

Novartis initiated a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia. CRS could lead to life-threatening complications in patients with COVID-19. The study builds on early evidence from lab tests of COVID-19 patients who showed elevated IL-1β levels, among other cytokines. Novartis aims to rapidly enroll 450 patients at multiple medical centers across France, Germany, Italy, Spain, UK and the US and randomize them to receive either canakinumab or placebo on top of standard of care (SoC). The primary objective of the study is to demonstrate the benefit of canakinumab in combination with SoC in increasing the chance of survival without the need for invasive mechanical ventilation among patients with COVID-19 pneumonia. Top-line results are anticipated late summer 2020. 


HVTN 405/HPTN 1901: The NIH-funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) have initiated their first clinical trial in response to COVID-19. The study, called HVTN 405/HPTN 1901, is underway at clinical trial sites across North and South America and will describe immune responses in study participants with a history of infection with SARS-CoV-2, the virus that causes COVID-19. HVTN 405/HPTN 1901 aims to enroll approximately 400 study participants aged 18 and older who tested positive for SARS-CoV-2 and have since recovered. Participants will have one required clinic visit and will have the option to participate in additional clinic visits two, four and twelve months after the initial visit. Each visit includes a blood draw and optional nasal sampling procedures. Individuals who still have symptoms of infection or asymptomatic individuals less than two weeks from the date of their last positive test will not be enrolled (May 14, 2020)


COVID-19 Potential Therapies​


COVID-19 Resources: Experimental Agent Review- Members from the Society of Infectious Diseases Pharmacists have prepared brief, evidence-based reviews of potential pharmacotherapeutic treatment options for COVID-19. These video presentations and handouts will be updated regularly as new data emerge on each of these experimental therapies.


COVID-19 vaccine and therapeutic research. The Milken Institute is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). Per the Milken Institute: "This document contains an aggregation of publicly-available information from validated sources. It is not an endorsement of one approach or treatment over another, but simply a list of all treatments and vaccines currently in development. Given the immediacy of the current public health emergency, we believe it is important to make the data accessible to the public in its current form. This overview will be updated as new findings come to light. We ask that you check this page on a regular basis."


There were reports that lopinavir/ritonavir (Kaletra) might have some anti-coronavirus activity. However, a paper published in the New England Journal of Medicine on March 18, 2020 reported that in hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. An accompanying editorial was published on March 18, 2020, at that provided important context and observations for this and future trials for people with COVID-19 disease.


From the Gilead website: Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing. These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19. The first of two studies will evaluate the safety and efficacy of both a 5-day and a 10-day dosing duration of remdesivir, in addition to standard of care, for patients with severe manifestations of COVID-19. The second study will evaluate the safety and efficacy of the same dosing regimens of remdesivir in addition to standard of care for patients with moderate manifestations of COVID-19, compared with standard of care alone. (Accessed March 24, 2020)
Interactions with experimental COVID-19 therapies. The Liverpool Drug Interaction Group (based at the University of Liverpool, UK), in collaboration with the University Hospital of Basel (Switzerland) and Radboud UMC (Netherlands), have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19. Please check this site regularly for updates and additional information. 


COVID-19 in patients with HIV: clinical case series. (From Lancet HIV-April 15, 2020)

Stability of SARS-CoV-2 (COVID-19 virus) on Surfaces


study published on March 17, 2020 in the NEJM found that aerosol and fomite transmission of SARS-CoV-2 is plausible, since the virus can remain viable and infectious in aerosols for hours and on surfaces up to days (depending on the inoculum shed). This study reinforces the importance of hand washing in addition to social distancing to reduce coronavirus transmission.


Webinars of Interest

AVAC was joined by Dr. Carl Dieffenbach, Director of the Division of AIDS (DAIDS) at the NIH, and other partners, to answer questions about what we do and don’t know about COVID-19 and HIV, how to track research developments on the HIV front, what this new pandemic might mean for ongoing HIV research, and how the HIV community can contribute to the fight against COVID-19.
COVID-19 & HIV Full Meeting (March 24, 2020)
The University of Washington AIDS Clinical Trials Unit’s Community Advisory Board (UW ACTU CAB) held an online meeting on March 24, 2020 focused on the COVID-19 pandemic. Dr. Rachel Bender Ignacio, Associate Director of the UW ACTU, presented and her excellent slides can be downloaded here:

​The Office of HIV/AIDS Network Coordination (HANC) hosted a webinar featuring Dr. Carl Dieffenbach​, Director of the Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases; Dr. Sarah Read, Deputy Director of the DAIDS; Manizhe Payton, Director of the Office of Clinical Site Oversight (OCSO) at DAIDS; and Dr. Jeffrey Schouten, HANC Director, in an effort to inform network stakeholders and community about the impact of COVID-19 on HIV research.
COVID-19: A clinical update for HIV care providers. (April 1, 2020) (hosted by the American Academy of HIV Medicine (AAHIVM) and Association of Nurses in AIDS Care (ANAC)). 
Finding the Middle Ground: Managing Stress and Anxiety During the COVID-19 Crisis. (May 7, 2020) Dr. Steven Safren and Dr. Deborah Jones Weiss from the University of Miami discuss stress and anxiety management strategies for providers during the COVID-19 epidemic. 
AVAC hosted an excellent webinar with Science Magazine’s Jon Cohen. (May 13, 2020) Jon talked about the fast-growing pipeline of vaccine candidates for COVID-19, how COVID-19 research is evolving and building on HIV vaccine research and more. The recording and terrific slides have been posted by AVAC.

The International AIDS Society (IAS) is organizing a series of webinars on the topic of COVID-19 and HIV to discuss the pandemic and its impact on people living with HIV. Through these webinar sessions, the IAS would like to provide an opportunity for discussion around the latest science, in addition to sharing learning and best practices in relation to COVID-19 and HIV between countries at different stages of the pandemic, especially in lower- and middle-income countries.​ Find links to the webinars here​

Remembering Gita Ramjee​ - From the MTN

We are writing to share the sad news about the passing of one of our very dearest colleagues, Gita Ramjee. The cause of death is from complications of COVID-19.
Words cannot express the sorrow we feel. Gita was a tremendous force within the field and was part of the MTN family from day one. As you all know she directed the MRC CTU in Durban for many years, and in May 2019 refocused her efforts toward spending more time with her sons living in London and enjoying her grandson who is about 6 months old. Gita had a tremendous passion for HIV prevention and she cared deeply about addressing the disparities in HIV incidence in young women. It wasn’t too long ago that she wrote in an email, “It has been a long road with many ups and downs but we have forged along with strong determination.” She was always impeccably dressed. She always had a beautiful manicure. She always had a big smile. We will always appreciate her role in the MTN family.
We will miss Gita and wish her family comfort during this time of unfathomable loss.
Stay well, stay safe.
Warmest wishes to all of you in this difficult time.
Sharon Hillier and Jared Baeten
(Posted  March 31, 2020)
Digg Delicious Facebook Newsvine Reddit StumbleUpon Twitter Email Link




© HIV/AIDS Network Coordination